Belzutifan for Recurrent Clear Cell Gynecologic Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of gynecologic cancer that is mostly clear cell (ovarian, endometrial, cervical, or related).
- You have already received at least one round of chemotherapy that included a platinum drug (like carboplatin or cisplatin).
- Your cancer has come back or continues to grow despite prior treatment.
- You are able to swallow pills and have adequate liver, kidney, and blood function as determined by standard tests.
- You have not taken belzutifan or a similar drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This study tests two investigational drugs, alone or together, for advanced ovarian clear cell cancer that has not responded to usual treatments. The goal is to see if these drugs help shrink or control the cancer.
This study tests an oral drug called belzutifan in teenagers with certain solid tumors. Belzutifan may shrink tumors by blocking a protein that helps them grow.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.